Latest Clinical News

FDA Approves Use of Xtandi for Chemotherapy Naïve Men With Advanced Prostate Cancer (09-15-2014)

The FDA approved the use of Xtandi® (enzalutamide) in men who have not yet received chemotherapy, significantly expanding the potential patient population eligible to be treated with the oral medicine.  Xtandi originally gained U.S. approval in 2012... Continue Reading

New Survey Reveals that Prostate Cancer Impacts Sex Lives More than Any Other Aspect of Patients’ Lives (09-11-2014)

Washington, DC (September 8, 2014) – A recent survey conducted by ZERO – The End of Prostate Cancer and Ferring Pharmaceuticals Inc. aimed to uncover the impact of prostate cancer on patients, their caregivers, and the healthcare professionals (HCPs)... Continue Reading

Promising Activity of Imbruvica Plus Rituxan in High-Risk CLL (09-10-2014)

Researchers from MD Anderson Cancer Center recently reported in the journal The Lancet Oncology that the combination of Imbruvica® (ibrutinib) and Rituxan® (rituximab) showed promising activity in the management of patients with high-risk chronic... Continue Reading

New Guidelines on Treatment of HER2-Negative Breast Cancer Aim to Improve Patient Outcomes (09-9-2014)

The American Society of Clinical Oncology (ASCO) recently released updated guidelines for the treatment of advanced HER2-negative breast cancer. The Journal of Clinical Oncology will publish the new guidelines, which include hormone therapy and sequential... Continue Reading

Molecular Subtyping Can Improve Breast Cancer Treatment (09-8-2014)

IRVINE, CA and AMSTERDAM – In findings that may eventually change the way breast cancer is evaluated and treated, a new study reports that the BluePrint genomic test provides more accurate information about the molecular subtype of a specific breast... Continue Reading

Pembrolizumab Gets FDA Approval in Advanced Melanoma (09-5-2014)

The U.S. Food & Drug Administration (FDA) has granted approval to Merck’s new immunotherapy drug, Keytruda (pembrolizumab), for treating metastatic melanoma.   It is the first anti-PD-1 drug, aimed at re-energizing a patient’s protective immune... Continue Reading

Adding Revlimid to R-CHOP May Improve Outomes of Selected Patients with NHL (09-4-2014)

The results of a recently completed study reported in the Journal of Clinical Oncology indicate that the addition of Revlimid® (lenalidomide) to R-CHOP the standard treatment for non hodgkin lymphoma (NHL) can overcome the negative prognostic effect... Continue Reading

Cabozantinib Development in Prostate Cancer Halted (09-3-2014)

Development of the investigational drug cabozantinib that initially showed promise in the treatment of metastatic, hormone-refractory prostate cancer has been halted due to discouraging results in a pivotal clinical trial.  Enrollment in a second, phase... Continue Reading

Anti-CD19 Chimeric Antigen Receptor (CAR) T Cells Reported to be Effective in Aggressive Non-Hodgkin’s Lymphoma at the National Cancer Institute (NCI) (09-3-2014)

SANTA MONICA, Calif., Aug. 25, 2014 (GLOBE NEWSWIRE) — Kite Pharma, Inc., (Nasdaq:KITE), a clinical-stage biopharmaceutical company focused on developing engineered autologous T cell therapy (eACT™) products for the treatment of cancer, announced... Continue Reading

Depression in Cancer Patients: What We Are Missing and What Can Be Done (09-2-2014)

Major depression is an important complication of cancer that can result in additional impairment of quality of life.  A series of three articles published in the Lancet presented new research on depression in people with cancer and confirmed that depression... Continue Reading

Interim Results of X-396 in ALK positive Non-Small Cell Lung Cancer Appear Promising (08-29-2014)

Preliminary results from a small phase 1 study of X-396, a novel anaplastic lymphoma kinase (ALK) inhibitor showed that X-396 is well tolerated and has antitumor activity in patients with ALK positive non-small cell lung cancer (NSCLC). Lung cancer is... Continue Reading

Risk of Breast Cancer Recurrence Doesn’t Increase with TNF Inhibitor Use (08-28-2014)

According to the results of a recently published study from Swedish investigators treatment with tumor necrosis factor inhibitors (TNF) does not appear to increase the rate of breast cancer recurrence among patients with rheumatoid arthritis (RA).  The... Continue Reading

Next Page »